The week of August 5 in review, featuring articles and physician interviews on tamoxifen in BRCA-positive patients, advances in melanoma, and the MAGE-A3 protein in lung cancer.
TweetSilvia Novello, MD, PhD, Assistant Professor, Thoracic Oncology Unit, University of Turin, San Luigi Hospital, Orbassano, Italy, gives an overview of immunotherapy and the targeting of the MAGE-A3 protein in lung cancer.
A quick reference chart of the key clinical trials presented at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting.
Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.
At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology.
Debu Tripathy, MD, Co-Leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, discusses the treatment of breast cancer with anthracyclines and trastuzumab.
A pooled analysis of three large cohort studies found that tamoxifen reduced the chances of developing contralateral or secondary breast cancer by more than half in patients with mutations ofBRCA1orBRCA2.
Bone is a particularly fertile site for the development of metastases. Prostate cancer cells shed from the primary tumor enter the circulation and release growth factors, cytokines, and other proteins which promote adhesion and proliferation to the bone.
Until recently, the cornerstone of therapy for metastatic melanoma had been chemotherapy with dacarbazine (DTIC) and immunotherapy with high-dose interleukin-2 (HD IL-2) or interferon-α (IFN-α).
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses the results of a trial looking at LDK378 for patients with ALK+ crizotinib-resistant non-small cell lung cancer.